Linking MLL Leukemia with Integrin Signaling

Cancer Cell. 2013 Jul 8;24(1):5-7. doi: 10.1016/j.ccr.2013.06.011.

Abstract

Identification of tractable signaling molecules essential for leukemogenesis facilitates the development of effective targeted therapies. In this issue of Cancer Cell, Miller and colleagues report that Integrin Beta 3, which is largely dispensable for normal hematopoiesis, plays an important role and is a potential therapeutic target in mixed lineage leukemia.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Histone-Lysine N-Methyltransferase
  • Humans
  • Integrin beta3 / physiology*
  • Intracellular Signaling Peptides and Proteins / physiology
  • Leukemia, Myeloid, Acute / etiology*
  • Myeloid-Lymphoid Leukemia Protein / physiology*
  • Oncogene Proteins, Fusion / physiology
  • Protein-Tyrosine Kinases / physiology
  • Signal Transduction / physiology*
  • Syk Kinase

Substances

  • Integrin beta3
  • Intracellular Signaling Peptides and Proteins
  • KMT2A protein, human
  • MLL-AF9 fusion protein, human
  • Oncogene Proteins, Fusion
  • Myeloid-Lymphoid Leukemia Protein
  • Histone-Lysine N-Methyltransferase
  • Protein-Tyrosine Kinases
  • SYK protein, human
  • Syk Kinase